Align Technology (ALGN) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenues reached $1.0124 billion, up 3.4% sequentially but down 1.6% year-over-year, with strong Systems and Services growth offset by a slight decline in Clear Aligner revenues due to lower volumes in Europe and North America; foreign exchange provided a favorable impact.

• Operating margin improved to 16.1%, up 2.7 pts sequentially and 1.7 pts year-over-year, with diluted EPS at $1.72, up $0.45 sequentially and $0.43 year-over-year; net income was $125 million.

• Macroeconomic headwinds, including tariff uncertainty, inflation, and reduced consumer confidence, led to lower patient traffic and fewer orthodontic case starts.

• The company is implementing significant restructuring actions in H2 2025, including workforce reductions, manufacturing optimization, and asset disposals, incurring $150–$170 million in one-time charges.

Financial highlights

• Q2 2025 total revenues: $1.0124 billion (+3.4% Q/Q, -1.6% Y/Y); Clear Aligner revenues: $804.6 million (+1.0% Q/Q, -3.3% Y/Y); Systems and Services revenues: $207.8 million (+13.9% Q/Q, +5.6% Y/Y).

• Gross margin: 69.9% (GAAP), slightly down from 70.3% in Q2 2024; non-GAAP gross margin: 70.9%.

• Operating income: $163 million; operating margin 16.1% (GAAP), 21.3% (non-GAAP).

• Net income: $125 million; diluted EPS: $1.72 (GAAP), $2.49 (non-GAAP).

• Cash and equivalents: $901.2 million as of June 30, 2025; free cash flow for Q2: $107.2 million.

Outlook and guidance

• Q3 2025 revenues expected at $965M–$985M, down sequentially due to seasonality and one-time charges; Clear Aligner and Systems and Services revenues both expected to decline.

• Q3 2025 GAAP gross margin projected at 64–65% (down 5–6 pts Q/Q) due to $45M–$55M in one-time charges; GAAP operating margin at 10.5–11.5%; non-GAAP at ~22%.

• FY2025 Clear Aligner volume growth expected in low single digits; revenue growth flat to slightly up; GAAP operating margin 13–14% (down 1–2 pts Y/Y) due to $150M–$170M in one-time charges; non-GAAP margin slightly above 22.5%.

• FY2025 capital expenditures forecasted at $100M–$125M, mainly for technology upgrades and manufacturing capacity.

• $1.0 billion share repurchase program authorized in April 2025, with $200 million planned for open market repurchases in H2 2025 and Q1 2026.